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Protein therapy holds great promise for treating a variety of diseases. To act on intracellular 
targets, therapeutic proteins must cross the plasma membrane. This has previously been achieved 
by covalent attachment to a variety of cell-penetrating peptides (CPPs). However, there is limited 
information on the relative performance of CPPs in delivering proteins to cells, specifically the cytosol 
and other intracellular locations. Here we use green fluorescent protein (GFP) as a model cargo to 
compare delivery capacity of five CPP sequences (Penetratin, R8, TAT, Transportan, Xentry) and 
cyclic derivatives in different human cell lines (HeLa, HEK, 10T1/2, HepG2) representing different 
tissues. Confocal microscopy analysis indicates that most fusion proteins when incubated with 
cells at 10 µM localise to endosomes. Quantification of cellular uptake by flow cytometry reveals 
that uptake depends on both cell type (10T1/2 > HepG2 > HeLa > HEK), and CPP sequence 
(Transportan > R8 > Penetratin≈TAT > Xentry). CPP sequence cyclisation or addition of a HA-sequence 
increased cellular uptake, but fluorescence was still contained in vesicles with no evidence of endosomal 
escape. Our results provide a guide to select CPP for endosomal/lysosomal delivery and a basis for 
developing more efficient CPPs in the future.
The delivery of functional proteins to cells offers potential for therapeutic intervention. Many human diseases 
are associated with malfunction or dysregulation of a specific protein, and provision of an intact protein to the 
diseased cell is a viable alternative to peptide and nucleotide based therapies1. Small-molecule drugs cannot nor-
mally mimic the highly specific and complex roles of proteins in cells and often generate adverse side effects. 
Protein therapeutics are generally safer than genetic approaches as they do not require genome modifications, 
which can lead to the silencing of indispensable genes or induction of tumourigenesis2. Developing protein ther-
apeutics is also financially appealing, as the average clinical development and approval time is shorter than for 
small-molecule drugs3 and wide-reaching patent protection can often be obtained1.
Unlike conventional small-molecule drugs, most proteins are large and hydrophilic. Such characteristics mean 
they do not pass directly through the plasma membrane which restricts their use as therapeutics. Cell-penetrating 
peptides (CPPs) have shown potential for the delivery of a wide range of molecules, including large active proteins 
to enter cells via endocytosis4–6. Typically composed of 5–30 amino acids, CPPs are mostly positively charged at 
physiological pH due to the presence of several arginine and/or lysine residues. Different internalisation mecha-
nisms have been reported to be utilised by CPPs, including direct penetration across the plasma membrane and 
endosomal uptake via one or several endocytic pathways7. Direct translocation is often observed at relatively high 
CPP concentrations when they are attached to small molecules such as fluorophores4. Endocytosis is the most 
common uptake route for larger cargos such as proteins; hence endosomal escape is required for protein to reach 
the cytosol and other subcellular locations8. Cyclic CPPs have recently been shown to promote highly efficient 
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cytosolic delivery of proteins and RNA9,10 suggesting that modifications in sequence arrangement, beyond chang-
ing amino acid residues, can enhance delivery capacity.
Since the discovery that HIV Tat protein can penetrate mammalian cells and enter the nucleus11, hundreds of 
peptides that have the capacity to enter cells have been identified and, to various extents, characterised4. However, 
a thorough comparative investigation into the relative potential of different CPPs for intracellular delivery of 
protein cargos is missing12–14. The wealth of available CPPs literature is characterised by significant experimental 
differences (e.g. cargo, CPP concentration, cell type, incubation time, etc) thus, it is difficult to draw clear conclu-
sions about the relative performance of different CPPs from these investigations.
Here we compare the ability of five CPPs (Penetratin, R8, TAT, Transportan, Xentry) and their derivatives 
(cyclic R8, cyclic TAT, HA-TAT) under identical experimental conditions to promote the cellular uptake of green 
fluorescent protein (GFP) in four cell lines of different tissue origins (HeLa – human cervical epithelial, HEK 
– human kidney epithelial, 10T1/2 – mouse embryonic, HepG2 – human liver epithelial). GFP was used as the 
model cargo due to the ease of visualising and quantifying its cellular uptake by fluorescence measurements. The 
results presented here indicate a very large variation in efficiency of cellular uptake as a function of CPP sequence, 
cyclisation and cell line. Furthermore, there are also distinct differences in the special subcellular profiles of the 
fluorescent cargo. The analysis provides a helpful guide for the choice of CPP for cargo delivery into endosomes 
and lysosomes, and a basis for developing more efficient CPPs in future.
Results
Optimising recombinant production of chimeric GFP and CPP fusion protein. In this study, R10, 
composing of ten consecutive arginine residues, was initially used as the model CPP to establish a recombinant 
protein expression system. Oligoarginine sequences between eight and twelve consecutive residues long have 
been shown to transduce small molecules into mammalian cells14–16. A DNA sequence corresponding to R10 
was added to the N-terminus of superfolder GFP (sfGFP) within the plasmid vector pBAD17, which contains an 
arabinose-inducible sfGFP gene with a C-terminal His tag. However, gene expression in Escherichia coli TOP10 
cells yielded no recombinant R10-sfGFP. In contrast, over 30 mg/L of unmodified sfGFP was obtained under the 
same expression conditions. It is known that addition of a CPP sequence can have a negative influence on recom-
binant protein yield10, therefore we swapped the position of CPP and His tag (i.e. having His tag at the N-terminus 
and CPP at the C-terminus) in the pBAD plasmid (Fig. S1a) and attempted to produce sfGFP-R10 (Fig. S1b) in 
TOP10 cells. Although the fluorescent protein obtained after purification showed a single band on SDS-PAGE, 
mass spectrometry (MS) analysis revealed only two Arg residues present at the C-terminus (Fig. S1c). Such trun-
cations were also observed in sfGFP-TAT and sfGFP-Transportan constructs (Figs. S2–S5). Specifically, only a 
truncated protein was observed for sfGFP-TAT (Fig. S3), whereas several truncated species and a trace amount of 
full-length protein were observed for sfGFP-Transportan (Fig. S4). For all experiments, protease inhibitors were 
present at purification steps and the presence of truncated proteins is most likely due to the endogenous protease 
activity in E. coli TOP10 cells that degrade the proteins in the cytoplasm.
To minimise the undesired proteolytic cleavage during protein expression, E. coli BL21(DE3)pLysS, which 
lacks the proteases Lon and OmpT, was investigated. Expression using pBAD vectors in BL21(DE3)pLysS gave 
a lower amount of sfGFP without a CPP present. Therefore, we switched to pEV vector, as this system is proven 
to produce high levels of enhanced GFP (eGFP) carrying a C-terminal R8 sequence in BL21(DE3)pLysS18. 
Expression of eGFP-R8 in BL21(DE3)pLysS gave a yield similar to that of eGFP without a CPP, and only the full 
length protein was obtained (Fig. 1a and Table 1). Thus, we decided to switch to R8 and eGFP as the model CPP 
and the model cargo, respectively. Different CPP sequences were cloned into the C-terminus of GFP in pEV eGFP 
plasmid (Fig. S6) that contains an inducible eGFP gene with an N-terminal His tag. Fusion proteins containing 
Penetratin, Transportan, Xentry, or TAT were obtained as full-length proteins (Figs. 1 and S7). However, attempts 
to produce eGFP containing another two commonly used CPPs, Integrin and MAP14, were not successful due 
to a mixture of full-length and truncated proteins being present after purification (Fig. S8). It was not possible 
to obtain pure full-length eGFP-Integrin or eGFP-MAP by either size-exclusion or ion-exchange chromatogra-
phy, and the constructs were omitted from subsequent cellular uptake experiments. Additionally, eGFP-Xentry 
appeared to exist predominantly as a dimer (Fig. S9), most likely due to formation of an intermolecular disulphide 
linkage from the cysteine residue in the Xentry sequence.
Cellular uptakes of eGFP-CPP. Confocal microscopy was initially employed to assess internalisation of 
the different eGFP-CPP fusion proteins. HeLa cells were incubated with 10 µM of proteins at 37 °C for 1 h under 
cell culture conditions then washed with heparin sulphate solution and culture media before imaging. Heparin 
sulphate is highly negatively charged and should minimise the presence of positively charged eGFP-CPP fusion 
proteins that associated with the plasma membrane4. In the absence of CPP, no cell-associated fluorescence was 
observed (Fig. 1b), refuting the possibility that His tag or eGFP itself may facilitate cellular uptake. Prominent 
eGFP-R8 and eGFP-Transportan uptake was observed in punctate structures but the fluorescence subcellular 
distribution and thus labelling pattern was very different. While eGFP-R8 is enriched in a perinuclear localisa-
tion, eGFP-Transportan displays punctate fluorescence towards the periphery of the cells. Both eGFP-Penetratin 
and eGFP-TAT also display perinuclear enrichment, similar to that seen using eGFP-R8, albeit with reduced 
levels of internalisation. With all three of these sequences (R8, Penetratin and TAT) being predominantly cat-
ionic, there may be similarities in terms of uptake mechanism over the more hydrophobic eGFP-Transportan. 
eGFP-Xentry also contains mainly hydrophobic residues, however, due to its low uptake levels it is difficult to 
determine if there are similarities between this sequence and eGFP-Transportan with respects to subcellular 
distribution.
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Figure 1. Cellular entry of eGFP-CPP fusion proteins. (a) SDS-PAGE of recombinant eGFP-CPP fusion 
proteins stained using Coomassie blue. (b) Confocal microscopy images of HeLa cells treated with eGFP-CPP 
fusion proteins. Cells were incubated with 10 µM of eGFP-CPP (green) at 37 °C for 1 h before imaging. Nuclei 
were stained with Hoechst (blue) before imaging. (c) Quantification of eGFP-CPP fusion protein uptake 
by cells. Cells were treated with 10 µM of eGFP-CPP fusion proteins at 37 °C for 1 h before analysis by flow 
cytometry. Geometric mean values of green fluorescence from living cells were recorded in each experiment. 
Values shown here are mean ± standard deviation from three independent experiments. There is a statistically 
significant difference between different CPPs in the same cell line as determined by one-way ANOVA (HeLa: 
F(6,14) = 17.89, p = 7.9 × 10−6; HEK: F(6,14) = 46.48, p = 1.9 × 10−8; 10T1/2: F(6,14) = 30.37, p = 3.0 × 10−7; 
HepG2: F(6,14) = 31.42, p = 2.4 × 10−7). Exact fluorescence intensity values are shown in Supplementary 








No CPP — 27875.52 27875.00 32
Penetratin RQIKIWFQNRRMKWKK 30104.26 30104.00 21
R8 RRRRRRRR 29125.02 29124.50 30
TAT YGRKKRRQRRR 29417.35 29417.00 31
Transportan GWTLNSAGYLLGKINLKALAALAKKIL 30698.98 30698.50 11
Xentry LCLRPVG 28614.47 28615.50 31
cR8 CRRRRRRRRC 29329.30 29329.00 27
cTAT CYGRKKRRQRRRC 29621.63 29620.00 13
HA-TAT GDIMGEWGNEIFGAIAGFLGYGRKKRRQRRR 31453.64 31453.50 14
Table 1. Molecular weight and expression yield of eGFP-CPP fusion proteins. aAll constructs contain an N-
terminal His-tag. The exact amino acid sequence of each construct is shown in Supplementary Fig. S6. bR8 
sequence is shown in italic and TAT sequence is shown in bold. The two Cys residues in the cR8 and cTAT 
constructs form a disulphide bond and cyclic structure of CPP. cMS spectra are shown in the Supplementary 
Fig. S7.
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The punctate signal seen in all CPP constructs is indicative of endocytosis being involved in the uptake mech-
anism, the lack of unified green fluorescence signals in the cytosol suggests that none of the CPPs promote high 
levels of endosomal escape. We cannot however, rule out the possibility that a small fraction of proteins has 
entered the cytosol but falls under the detection limit of confocal microscopy.
To quantify cellular uptake across a range of differing cell lines, cells treated with eGFP-CPP constructs were 
subjected to flow cytometry analysis. Following incubation with each eGFP-CPP protein at 37 °C for 1 h, cells 
were washed with heparin sulphate solution and culture media, trypsinised and subjected to flow cytometry. 
The mean fluorescent intensity was calculated from three biological replicas of the geometric mean fluorescence 
of each eGFP-CPP fusion protein in the different cell lines (Fig. 1c and Table S1). While cells treated with eGFP 
without a CPP showed negligible fluorescence, cells incubated with all the other eGFP-CPP fusion proteins dis-
played a substantial fluorescence reading (Table S2). The fluorescence intensity depended on both cell type and 
CPP sequence. 10T1/2 cells showed the highest level of uptake of the cationic peptides (Penetratin, R8 and TAT), 
and the increased uptake was seen for all peptides when compared to the internalisation by both HeLa and HEK 
cells (Tables S1 and S3). It is interesting to note the very high uptake of eGFP-Transportan seen in HepG2 cells 
that is not seen with any of the other peptides that show comparable uptake. Overall, the performance of individ-
ual CPPs in the four cell lines has the general trend of Transportan > R8 > Penetratin≈TAT > Xentry (Tables 2 
and S2). It is noteworthy that none of the CPPs seem to cause any toxicity in HeLa cells (Fig. S10).
Modification of CPP to enhance cellular uptake. Cyclisation of CPPs have recently been shown to 
increase cellular uptake19 and promote direct translocation of CPP-conjugated proteins into the cytosol9,10. To 
form a cyclic structure, we introduced a cysteine residue at each side of the CPP sequence (i.e. Cys-CPP-Cys), and 
a disulphide bond was expected to form between the two cysteine residues and cyclise two ends of the CPP. This 
should occur in all tested CPPs apart from Xentry which contains an endogenous cysteine.
In addition to cyclisation, we also investigated if addition of a well characterised endosomal escape sequence 
from the influenza virus haemagglutinin protein (HA)20,21 enhanced cellular uptake and/or cytosolic delivery. The 
peptide was introduced between eGFP and TAT; TAT-HA has been shown to deliver proteins into cells, specifi-
cally the cytosol and nucleus20,21.
Following the same expression protocol, we were able to obtain eGFP-HA-TAT and eGFP with a C-terminal 
cyclic Penetratin (cPenetratin), cyclic R8 (cR8) or cyclic TAT (cTAT) (Fig. S11), although the yield of 
eGFP-cPenetratin (3.5 mg/L) was significantly lower than the other variants (Table 1). Only truncated products 
were observed for eGFP-cTransportan and eGFP-HA-cTAT under the previously validated expression condition. 
When raising the expression temperature from 20 °C to 37 °C, full-length eGFP-cTransportan was discovered in 
the insoluble fraction upon cell lysis. However, refolding of insoluble protein under various conditions was not 
successful (data not shown). Thus, we proceeded the investigation with cPenetratin, cR8, cTAT and HA-TAT.
Compared with linear CPPs, confocal microscopy showed a visibly increased fluorescence signal after either 
cyclisation or addition of the HA peptide (Fig. 2a), a finding that is supported by flow cytometry analysis of the 
same conjugates (Fig. 2b). Interestingly the localisation of both eGFP-R8 and eGFP-TAT upon cyclisation was dif-
ferent to the linear variants. CPP cyclisation changed the localisation to a more peripheral position within the cell, 
with a signal more aligned to that seen using eGFP-Transportan. Comparing eGFP-cTAT and eGFP-HA-TAT, 
both variants also show differences in localisation, with eGFP-cTAT more scattered throughout the cell and 
eGFP-HA-TAT showing some perinuclear enrichment.
No significant endosomal escape was observed using any of the peptides although, again, low level escape is 
difficult to detect (Fig. 2a). Attempts to image eGFP-cPenetratin produced images dominated by protein aggre-
gates (Fig. S12). During purification of eGFP-cPenetratin, protein precipitation was frequently observed when 
concentrating this construct. This was not observed with the other variants, indicating the intrinsic instability of 
eGFP-cPenetratin.
Flow cytometry analysis in different cell lines confirmed that cyclisation of either R8 or TAT increases cellular 
uptake (Fig. 2b and Table 3). All cell types showed an increase in uptake in response to cyclisation (Tables S4 and 
S5) with HeLa producing the largest response with a 4.0- and 5.9-fold increase in fluorescence of R8 and TAT, 
respectively (p = 0.0034 and 0.0004 in t-tests). Addition of the HA sequence to TAT also increased the uptake 
across all four cell lines. However, this increase was not to the same extent as cTAT. Confocal microscopy of 
TAT-HA in HeLa cells showed that fluorescence was localised to vesicular structures with no evidence of high 
level endosomal escape.
Since cyclic CPP was reported to enable direct translocation into cells at higher concentration (>50 µM)9, 
HeLa cells were treated with 100 µM eGFP-cR8 or eGFP-cTAT and analysed by confocal microscope (Fig. S13). 
Cytoplasmic punctate green fluorescence was still observed in all cases, indicating the vast majority of cellular 
uptake had occurred by endocytosis.
Cell Only No CPP Penetratin R8 TAT Transportan Xentry
Meana 7 14 78 127 79 189 31
Stda 1.59 1.65 1.95 1.84 1.91 2.61 1.58
Table 2. Relative performances of five CPPs in four cell lines. aGeometric mean and geometric standard 
deviation are shown here.
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Discussion
In this work, we directly compared the cell-penetrating ability of seven CPPs, Penetratin, R8, Transportan, Xentry, 
TAT, TAT-HA, cTAT to deliver eGFP into four different cell lines. The cationic peptides TAT11 and Penetratin22 
were among the first CPPs to be discovered and, along with synthetic oligoarginine sequences, they have been 
widely used to promote cellular uptake of different cargos in vitro and in vivo4. The more hydrophobic, amphip-
athic Transportan was found to be the most efficient CPP among 22 sequences for delivering an organic fluoro-
phore into mammalian cells14, and our data reveal that Transportan is extremely efficient at delivering eGFP 
to HepG2 cells. Xentry is a relatively new class of CPP and preferentially enters cells expressing high levels of 
syndecans (e.g. HepG2)23. Because of their previously reported ability to deliver small molecule cargoes14, we 
also attempted to assess the capacity of Integrin peptide and MAP14 to deliver a protein load, but these constructs 
proved difficult to express and purify under our optimised conditions.
Figure 2. Green fluorescence intensity of cells treated with eGFP proteins fused to a modified CPP. 
Experimental conditions were the same as described in Fig. 1. (a) Confocal microscopy images. (b) 
Quantification by flow cytometry. There is a statistically significant difference between different CPPs in the 
same cell line as determined by one-way ANOVA (HeLa: F(6,14) = 46.42, p = 2.0 × 10−6; HEK: F(6,14) = 115.5, 
p = 4.0 × 10−11; 10T1/2: F(6,14) = 37.13, p = 8.0 × 10−8; HepG2: F(6,14) = 136.5, p = 1.0 × 10−11). Exact 
fluorescence intensity values are shown in Supplementary Table S4. Pairwise statistical analyses are shown in 
Supplementary Tables S5 and S6.
Cell Only No CPP R8 cR8 TAT cTAT HA-TAT
Meana 3 9 112 294 89 356 201
Stda 1.31 1.33 2.15 2.12 2.17 1.97 1.91
Table 3. Relative performances of five CPPs in four cell lines. aGeometric mean and geometric standard 
deviation are shown here.
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As many CPPs share common features with anti-microbial peptides24,25, we needed to modify our standard 
bacterial expression system to obtain a yield that would allow for subsequent analysis. Our initial attempt to 
generate a construct with an N-terminal CPP conjugated to sfGFP in E. coli TOP10 produced a low yield of the 
desired product, despite sfGFP alone being produced at a high yield. The low yield of R10-sfGFP is most likely 
due to the presence of Arg residues at the N-terminus, which can shorten the half-life of a protein to ca. 2 min26. 
To overcome this, CPPs were appended at the C-terminus of the constructs for expression in TOP10 cells. Very 
low yields were again observed, most likely due to proteolytic cleavage of the recombinant proteins in the cyto-
plasm. Changing the expression host to BL21(DE3)pLysS, which lacks proteases Lon and OmpT, results in much 
higher expression. This highlights the importance of using bacteria that have low protease activity in preparing 
CPP-fused proteins. The decision was also made to switch from sfGFP to eGFP-R818 as this variant is more suita-
ble for production at 37 °C27, a temperature we show to reduce truncation artefacts in our system. However, trun-
cated proteins were still observed when producing eGFP-Integrin and eGFP-MAP in BL21(DE3)pLysS (Fig. S8). 
Integrin and MAP are probably sub-ideal choices of CPP for producing recombinant CPP fusion protein and 
methods for generating such constructs require optimisation before we can study their delivery capacity.
Addition of a peptide sequence that interacts with endosomal membranes has been shown to influence the 
ability of CPPs to deliver molecules to the cytosol8, a critical step required if the cargo target resides in the cytosol. 
HA-TAT peptide has previously been used to deliver peptides and proteins into the cytosol and then trafficked 
to the nucleus20,21. Cyclisation of TAT or R8 has been proven to increase the cellular uptake of an organic fluoro-
phore19 and was hypothesised that cyclisation increases peptide structural rigidity and contact areas with mem-
brane, leading to enhanced cell penetration19. Most importantly, cyclic TAT and cyclic R8 were demonstrated to 
enable efficient cytosolic delivery of protein cargos through direct plasma membrane translocation9,10, a phenom-
enon not observed in the linear counterparts. Consequently, we put the CPP sequence in-between two cysteine 
residues, which form a disulphide bond in situ and hence generate a cyclic structure. Our strategy allows the 
production of recombinant proteins containing a cyclic CPP in a single set of procedures. Further, it is economi-
cally favoured over previously reported methods where cyclic TAT peptide and the protein cargo were separately 
produced by solid-phase peptide synthesis and recombinant expression in E. coli. They were then subsequently 
linked together by bioconjugation chemical reactions9,10.
Here, cell lines from different species and tissues were tested for cellular uptake of eGFP-CPP. HeLa is a cervi-
cal cancer cell line and the most commonly used cell in CPP studies13, HEK is a widely-used non-cancer mamma-
lian cell line, 10T1/2 is fibroblast, a different morphology to the other three cell lines which are epithelial, whilst 
HepG2 is a liver cancer cell line and was used in the previous characterisation of Xentry23.
In line with other studies for first line analyses, we have performed these experiments in serum free media 
to avoid complexation of the constructs to serum proteins such as albumin, while preventing degradation by 
serum proteases4,13–16,18–20,23,28–30. We used confocal microscopy to access the cellular uptake by the fusion of CPP 
and the subcellular localisation of the model cargo protein, eGFP. Theoretically, positively charged CPP proteins 
can associate with the negatively charged cell membrane via ionic interaction without being internalised into 
cells4. This possibility was ruled out by the confocal microscopy results, which clearly illustrate that all CPPs can 
promote the cellular uptake of eGFP, although all eGFP-CPP fusion proteins seem to localise predominantly in 
endosomes (Fig. 2). Indeed, localisation of protein cargos within the endosomes was expected for all CPPs except 
HA-TAT, cTAT and cR8 which have been reported to promote release into the cytosol9,10,20. It is possible that the 
HA sequence has a small positive effect on endosomal escape, as the confocal images do not exclude the possibil-
ity that a small amount of protein localises in the cytosol or nucleus. For cyclic TAT, it has been reported that this 
sequence can be internalised into HeLa cells with immediate bioavailability in the cytosol9. This conclusion differs 
from our observations and may be attributed to experimental differences. In the previous report, a mixture of D- 
and L- amino acids were used and the resulting CPP (rRrGrKkRr) may have alternative biophysical properties9. 
In our studies, the cyclic linkage was made via disulphide bond formation whilst an isopeptide bond between 
lysine and glutamic acid was used by Nischan et al.9.
Our quantitative cellular uptake analysis gives a general trend of cTAT > cR8 > HA-TAT≈Transportan > R8 
> Penetratin≈TAT > Xentry for the CPPs examined (Tables 2, 3, S2 and S5) and 10T1/2 > HepG2 > HeLa > HEK 
for the cell lines tested (Tables S1, S3, S4 and S6). Overall, the flow cytometry results are qualitatively in agree-
ment with the confocal microscopy observations (Figs 1 and 2). The observed trend is also in agreement with 
previous studies using organic fluorophores, where cellular uptake is generally higher in HeLa than HEK cells14; 
Transportan outperformed both Penetratin and TAT13,14; and cyclisation increased the cellular uptake promoted 
by TAT19. To our surprise, there was little uptake of eGFP-Xentry in any cell line, including HepG2 which was 
used to establish this peptide as a CPP for the delivery of organic fluorophores, proteins and nucleic acids23. Since 
replacement of the cysteine residue in the Xentry with a leucine totally abolished the cell-penetrating ability29, 
the minimal uptake of eGFP-Xentry is probably due to the formation of dimer through the cysteine residue in 
the Xentry sequence. However, cysteine residues are prone to form disulphide bonds under normal atmospheric 
conditions, so the need of a free cysteine residue for Xentry means that Xentry conjugates have to be preserved in 
the absence of oxygen and/or with reducing reagents, an unattractive requirement for developing therapeutic pro-
teins. Both HA-TAT and cTAT showed higher cellular uptake as quantified by the fluorescence intensity (Fig. 2b). 
One possibility for the higher fluorescence intensity observed with eGFP-HA-TAT could be a consequence of the 
endosomolytic activity of the HA peptide. This peptide has been shown to permeabilise endosomal membranes 
without releasing the fusion protein cargo to cytosol28. Once endosomal membranes are permeabilised, the endo-
somal pH is likely to increase towards neutral (i.e. cytosolic pH), consequently leading to higher fluorescence 
intensity of eGFP, which is brighter at pH neutral and basic environments31.
Lastly, the effect of cyclisation is in agreement with the previous study using an organic fluorophore19, suggest-
ing a universal effectiveness of this approach to enhance cellular uptake.
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The localisation of eGFP (after internalisation using different peptides) changes in HeLa cells, and it would 
be of great interest to deduce the intracellular compartment these peptides are locating to. For treatments of 
lysosomal storage diseases, rapid trafficking to the lysosome would be of large benefit. However, if a CPP-protein 
were to be used in conjunction with a method of endosomal escape, slower trafficking to the lysosome may be 
more appropriate. At 10 µM none of the peptides displayed evidence of cytosolic delivery, although more sensitive 
methods need to be employed to precisely determine this property. Nevertheless, these CPPs would be useful 
for delivering protein cargos to endosomes and lysosomes for treatments of diseases where the protein needs, or 
targets lie in, these organelles32.
Conclusions
Here we provide comparative data for the performance of different CPPs in four cell lines. Our approach is sim-
ple, using only an optimised recombinant method. Protease degradation limits the choice of CPPs for obtaining 
fusion proteins. However, we have shown high yield production of both linear and cyclic TAT and R8 and linear 
Transportan. Our confocal and flow cytometry data further suggest that cyclisation of CPPs enhances cellular 
uptake, but it remains to be determined if this modification also increases endosomal escape of protein cargoes 
(i.e. toxins) that have influences on cellular physiology if they reach the cytosol.
Methods
Construction of eGFP-CPP plasmids. Plasmids pEV eGFP and pEV eGFP-R8 were described previ-
ously18. The vector for a plasmid that expresses Penetratin, Xentry, TAT or cTAT fused to eGFP was PCR amplified 
from pEV eGFP with primers TGAGAATTCAAGCTTAAGCTGAGCAATAACTAGC and CCATGTGGTGGTG 
GTGGTGGT GCATATGTATATCTC, and the eGFP-CPP sequence was PCR amplified from pEV eGFP with the 
forward primer CCACCACCACCACCACATGGTGAGCAAGGGCGAG and the corresponding reverse primer 
AGCTTAAGCTTGAATTCTCAGCCCACGCCCACGCCCGCCAGCGCGCCCAGC GCCAGCACGGTCAC 
CTTGTACAGCTCGTCCATGCCGAGAG (Penetratin), A GC TT AA GC TTGAA T TC TC AC GC CA GT TT CA GC-
GC CG CT TT CA GC GC TT TC AG CG CC AG TT TC AG CG CC AG TTTCTTGTACAGCTCGTCCATGCCGAGAG 
(Xentry), AGCTTAAGCTTGAATTCTCATTTCTTCCATTTCA TACGGCGGTTCT GGAACCAGATTTTAA 
TTTGACGCTTGTACAGCTCGTCCATGCCGAGAG (TAT) or AGCTTAAGCTTGAATTCTCAGCCCACCG 
GGCGCAGGCACAGCTTGTACAGCTCGTCCATG CCGAGAG (cTAT). PCR fragments were purified by 
gel extraction. Gibson assembly of the vector and the corresponding eGFP-CPP fragment afforded plasmids 
pEV eGFP-CPP. To construct pEV eGFP-Transportan, the vector was obtained from PCR amplification of pEV 
eGFP with primers A A A AT T A AC C T GA A A GC G C TG G C GG C G CT G G CG A A AA A A AT T C TG T G AG AA TT-
CAAGCTTAAGCTGAGCAATAACTAGC and CCATGTGGTGGTGGTGGTGGTGCATATGTATATCTC, 
and the insert was PCR amplified from pEV eGFP with primers CCACCACCACCACCACATGG TGAGCAAG 
GGCGAG and AGCTTAAGCTTGAATTCTCAGCAACGACGACGCTGACGACGTTT TTTACGACCGTAGCA 
CTTGTACAGCTCGTCCATG. PCR fragments were gel purified and subjected to two-piece Gibson assembly to 
afford pEV eGFP-Transportan. To construct pEV eGFP-TAT-HA, the vector was obtained from PCR amplification of 
pEV eGFP-TAT with primers GGTTTTCTGGGTTACGGTCGTAAAAAACGTCGTCAGCGTCGTCGTTGAG 
and CCATGTGGT GGTGGTGGTGGTGCATATGTATATCTC, and the insert was PCR amplified from pEV 
eGFP-TAT with primers CCACCACCACCACCACATGGTGAGCAAGGGCGAG and AGCTTAAGCTT 
GAATT C CT ACAGCAGGCGGCGCAGGGTGCGTTTGCGCACAATATGGCGGCGGCGCATAAACAGCTT
GTACAGCTCGTCCATGCCGAG. PCR fragments were gel purified and subjected to two-piece Gibson assem-
bly to afford pEV eGFP-TAT-HA.
Expression and purification of recombinant eGFP-CPP fusion proteins. The desired pEV 
eGFP-CPP plasmid was transformed into E. coli BL21(DE3)pLysS and plated on Luria-Bertani (LB) agar con-
taining ampicillin (100 µg/mL) and chloramphenicol (34 µg/mL). A single colony was grown in LB medium 
(50 mL) containing ampicillin (100 µg/mL) and chloramphenicol (34 µg/mL) at 37 °C with vigorous shaking. After 
overnight incubation, this culture was diluted 50 times into fresh LB (2 L) containing ampicillin (100 µg/mL) 
and chloramphenicol (34 µg/mL). The culture was incubated at 37 °C to OD600 0.9 before addition of isopropyl 
β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM. The culture was further incubated at 
20 °C overnight. Cells were then collected by centrifugation at 4 °C and 6,000 × g for 20 min. Pellets from the 2 L 
culture were re-suspended in 40 mL of pre-chilled lysis buffer (pH 7.5, 20 mM Tris-HCl, 400 mM NaCl, 20 mM 
imidazole) containing protease inhibitor (Roche, #05892953001) and lysozyme (1 mg/mL). The re-suspended 
cells were sonicated for 10 min (10 sec pulse ON and 30 sec OFF). The cell debris was then removed by centrifuga-
tion at 4 °C and 38,000 × g for 30 min, and the supernatant (i.e. cell lysate) was collected for purification.
XK16/20 column was packed with 10 mL Ni Sepharose 6 Fast Flow resin (GE Healthcare) and incubated 
with 50 mL of equilibration buffer (pH 7.5, 20 mM Tris-HCl, 400 mM NaCl, 20 mM imidazole), before loading 
the cell lysate. After the sample passed through the column, the column was washed with wash buffer (pH 6.3, 
20 mM Tris-HCl, 400 mM NaCl, 20–50 mM imidazole). eGFP-CPP was eluted with elution buffer (pH 7.5, 20 mM 
Tris-HCl, 250 mM NaCl, 250 mM imidazole). Fractions were collected and analysed by SDS-PAGE. Fractions 
containing eGFP-CPP identified by SDS-PAGE were pooled together. Proteins were concentrated to 100 µM and 
exchanged into phenol red free Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies, #31053-028) 
using a 10-kDa cut-off membrane (Millipore, #PLGC04310). Protein concentrations were determined by BCA 
assays.
Confocal microscopy. HeLa cells were seeded at a density of 3.5 × 105 cells per imaging dish (MatTek, 
#P35G-1.5-10-C) and grown at 37 °C in a 5% CO2 atmosphere in DMEM supplemented with 10% (v/v) FBS for 
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24 h. Cells were then incubated with 10 µM of the designated eGFP-CPP fusion protein in phenol red free DMEM 
(Life Technologies, #21063-029) and absence of serum at 37 °C for 1 h, followed by washing three times with 
heparin sulphate (Sigma, #H3149, 0.5 mg/mL in PBS) and twice with phenol red free DMEM. The nucleus was 
stained by incubation with Hoechst (1 µg/mL) in phenol red free DMEM at 37 °C for 5 min before imaging on a 
Leica TCS SP5 confocal microscope.
Flow cytometry. Cells were seeded at a density of 1 × 105 cells per well in a 24-well plate and grown at 37 °C 
in a 5% CO2 atmosphere in DMEM supplemented with 10% (v/v) FBS for 24 h. Cells were then incubated with 
10 µM of the designated eGFP-CPP fusion protein in phenol red free DMEM (Life Technologies, #21063-029) at 
37 °C for 1 h, followed by washing three times with heparin sulphate and twice with phenol red free DMEM for 
two times before addition of trypsin (50 µl/well; Corning, #25-052-CI). Trypsinised cells were diluted with PBS 
(0.45 mL) and analysed on a Bio-Rad S3e Cell Sorter for minimum 10,000 events per sample. Data were analysed 
on ProSort software (Bio-Rad), and geometric mean values of green fluorescence (526 nm) of live cells in each 
sample from excitation with a 488-nm laser were taken for quantification.
Data Statement
Information about the data underpinning the results presented here (i.e. confocal microscope image and flow 
cytometry files), including how to access them, can be found in the Cardiff University data catalogue at https://
doi.org/10.17035/d.2018.0064167981.
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